NF-κB binding activity and pro-inflammatory cytokines expression correlate with body mass index but not glycosylated hemoglobin in Chinese population

Diabetes Research and Clinical Practice

Volumn 90, Issue 1, 2010, Pages 73-80

  He, Lan ^a   He, Ming ^a   Lv, Xiaohong ^a   Pu, Dan ^a   Su, Peihe ^a   Liu, Zhiquan ^a  

^a XI'AN JIAOTONG UNIVERSITY   (China)

Author keywords

Chinese population; Glycosylated hemoglobin; Inflammation; Obesity; Type 2 diabetes

Indexed keywords

GELATINASE B; GLUCOSE; HEMOGLOBIN A1C; I KAPPA B ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 18; INTERLEUKIN 6; INTERLEUKIN 8; SYNAPTOTAGMIN I; TRANSCRIPTION FACTOR RELA; TUMOR NECROSIS FACTOR ALPHA; AUTACOID; CYTOKINE; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN; I KAPPA B; IL6 PROTEIN, HUMAN; MESSENGER RNA; NF KAPPAB INHIBITOR ALPHA; NF-KAPPAB INHIBITOR ALPHA;

ADULT; AGED; ARTICLE; BODY MASS; CHINESE; CHRONIC INFLAMMATION; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE; HUMAN; HUMAN CELL; INSULIN RESISTANCE; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PERIPHERAL BLOOD MONONUCLEAR CELL; PROTEIN BLOOD LEVEL; PROTEIN DNA BINDING; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; WESTERN BLOTTING; BLOOD; CHINA; GENETICS; METABOLISM; MIDDLE AGED; MONONUCLEAR CELL; PATHOPHYSIOLOGY; UNIVERSITY HOSPITAL;

ADULT; AGED; BLOOD GLUCOSE; BODY MASS INDEX; CHINA; CYTOKINES; DIABETES MELLITUS, TYPE 2; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HOSPITALS, UNIVERSITY; HUMANS; I-KAPPA B PROTEINS; INFLAMMATION MEDIATORS; INSULIN RESISTANCE; INTERLEUKIN-6; LEUKOCYTES, MONONUCLEAR; MALE; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; NF-KAPPA B; OBESITY; RNA, MESSENGER; TUMOR NECROSIS FACTOR-ALPHA;

EID: 77956190207     PISSN: 01688227     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diabres.2010.06.016     Document Type: Article

References (39)

1. Wilson P.W., D'Agostino R.B., Parise H., Sullivan L., Meigs J.B. Metabolic syndrome as a precursor of cardiovascular disease and type 2 diabetes mellitus. Circulation 2005, 112(20):3066-3072.
2. Chen K.W., Boyko E.J., Bergstrom R.W., Leonetti D.L., Newell-Morris L., Wahl P.W., et al. Earlier appearance of impaired insulin secretion than of visceral adiposity in the pathogenesis of NIDDM. 5-Year follow-up of initially nondiabetic Japanese-American men. Diabetes Care 1995, 18(6):747-753.
3. Ferrannini E., Gastaldelli A., Miyazaki Y., Matsuda M., Mari A., DeFronzo R.A. Beta-cell function in subjects spanning the range from normal glucose tolerance to overt diabetes: a new analysis. J Clin Endocrinol Metab 2005, 90(1):493-500.
4. Maedler K. Beta cells in type 2 diabetes-a crucial contribution to pathogenesis. Diabetes Obes Metab 2008, 10(5):408-420.
5. Meigs J.B., Rutter M.K., Sullivan L.M., Fox C.S., D'Agostino R.B., Wilson P.W. Impact of insulin resistance on risk of type 2 diabetes and cardiovascular disease in people with metabolic syndrome. Diabetes Care 2007, 30(5):1219-1225.
6. Tkác I. Metabolic syndrome in relationship to type 2 diabetes and atherosclerosis. Diabetes Res Clin Pract 2005, 68(S1):S2-S9.
7. Ansquer J.C., Foucher C., Aubonnet P., Le Malicot K. Fibrates and microvascular complications in diabetes-insight from the FIELD study. Curr Pharm Des 2009, 15(5):537-552.
8. Savage D.B., Petersen K.F., Shulman G.I. Disordered lipid metabolism and the pathogenesis of insulin resistance. Physiol Rev 2007, 87(2):507-520.
9. Johansen O.E. Cardiovascular disease and type 2 diabetes mellitus: a multifaceted symbiosis. Scand J Clin Lab Invest 2007, 67(8):786-800.
10. Dogru T., Sonmez A., Tasci I., Bozoglu E., Yilmaz M.I., Genc H., et al. Plasma visfatin levels in patients with newly diagnosed and untreated type 2 diabetes mellitus and impaired glucose tolerance. Diabetes Res Clin Pract 2007, 76(1):24-29.
11. Creely S.J., McTernan P.G., Kusminski C.M., Fisher F.M., Da Silva N.F., Khanolkar M., et al. Lipopolysaccharide activates an innate immune system response in human adipose tissue in obesity and type 2 diabetes. Am J Physiol Endocrinol Metab 2007, 292(3):E740-E747.
12. Hotamisligil G.S., Erbay E. Nutrient sensing and inflammation in metabolic diseases. Nat Rev Immunol 2008, 8(12):923-934.
13. Pickup J.C. Inflammation and activated innate immunity in the pathogenesis of type 2 diabetes. Diabetes Care 2004, 27(3):813-823.
14. Schmidt M.I., Duncan B.B., Sharrett A.R., Lindberg G., Savage P.J., Offenbacher S., et al. Markers of inflammation and prediction of diabetes mellitus in adults (atherosclerosis risk in communities study): a cohort study. Lancet 1999, 353(9165):1649-1652.
15. Pradhan A.D., Manson J.E., Rifai N., Buring J.E., Ridker P.M. C-reactive protein, interleukin-6, and risk of developing type 2 diabetes mellitus. JAMA 2001, 286(3):327-334.
16. Chen F., Castranova V., Shi X. New insights into the role of nuclear factor-kappaB in cell growth regulation. Am J Pathol 2001, 159(2):387-397.
17. Nathan C. Points of control in inflammation. Nature 2002, 420(6917):846-852.
18. Li Q.T., Verma I.M. NF-kappa B regulation in the immune system. Nat Rev Immunol 2002, 2(10):725-734.
19. Ghanim H., Aljada A., Hofmeyer D., Syed T., Mohanty P., Dandona P. Circulating mononuclear cells in the obese are in a proinflammatory state. Circulation 2004, 110(2):1564-1571.
20. Morigi M., Angioletti S., Imberti B., Donadelli R., Micheletti G., Figliuzzi M., et al. Leukocyte-endothelial interaction is augmented by high glucose concentrations and hyperglycemia in a NF-kappa B-dependent fashion. J Clin Invest 1998, 101(9):1905-1915.
21. Esposito K., Nappo F., Marfella R., Giugliano G., Giugliano F., Ciotola M., et al. Inflammatory cytokine concentrations are acutely increased by hyperglycemia in humans: role of oxidative stress. Circulation 2002, 106(16):2067-2072.
22. Rudofsky G., Reismann P., Schiekofer S., Petrov D., von Eynatten M., Humpert P.M., et al. Reduction of postprandial hyperglycemia in patients with type 2 diabetes reduces NF-kappa B activation in PBMCs. Horm Metab Res 2004, 36(9):630-638.
23. Hofmann M.A., Schiekofer S., Kanitz M., Klevesath M.S., Joswig M., Lee V., et al. Insufficient glycemic control increases nuclear factor-kappa B binding activity in peripheral blood mononuclear cells isolated from patients with type 1 diabetes. Diabetes Care 1998, 21(8):1310-1316.
24. American Diabetes Association Standards of medical care in diabetes-2007. Diabetes Care 2007, 30(S1):S4-S41.
25. World Health Organization Western Pacific Region and International Association for the Study of Obesity The Asia-Pacific perspective: redefining obesity and its treatment 2000.
26. Matthews D.R., Hosker J.P., Rudenski A.S., Naylor B.A., Treacher D.F., Turner R.C. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985, 28(7):412-419.
27. Xu H.Y., Barnes G.T., Yang Q., Tan Q., Yang D.S., Chou C.J., et al. Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J Clin Invest 2003, 112(12):1821-1830.
28. Kershaw E.E., Flier J.S. Adipose tissue as an endocrine organ. J Clin Endocrinol Metab 2004, 89(6):2548-2556.
29. Berg A.H., Scherer P.E. Adipose tissue, inflammation, and cardiovascular disease. Circ Res 2005, 96(9):939-949.
30. Aljada A., Mohanty P., Ghanim H., Abdo T., Tripathy D., Chaudhuri A., et al. Increase in intranuclear nuclear factor kappa B and decrease in inhibitor-kappa B in mononuclear cells after a mixed meal: evidence for a proinflammatory effect. Am J Clin Nutr 2004, 79(4):682-690.
31. Bierhaus A., Schiekofer S., Schwaninger M., Andrassy M., Humpert P.M., Chen J., et al. Diabetes-associated sustained activation of the transcription factor nuclear factor-kappa B. Diabetes 2001, 50(12):2792-2808.
32. Nelson D.E., Ihekwaba A.E., Elliott M., Johnson J.R., Gibney C.A., Foreman B.E., et al. Oscillations in NF-kappaB signaling control the dynamics of gene expression. Science 2004, 306(5696):704-708.
33. Hoffmann A., Levchenko A., Scott M.L., Baltimore D. The Ikappa B-NF-kappa B signaling module: temporal control and selective gene activation. Science 2002, 298(5596):1241-1245.
34. Li L., Sawamura T., Renier G. Glucose enhances human macrophage LOX-1 expression role for LOX-1 in glucose-induced macrophage foam cell formation. Circ Res 2004, 94(7):892-901.
35. Kern P.A., Ranganathan S., Li C.L., Wood L., Ranganathan G. Adipose tissue tumor necrosis factor and interleukin-6 expression in human obesity and insulin resistance. Am J Physiol Endocrinol Metab 2001, 280(5):E745-E751.
36. Bastard J.P., Maachi M., Lagathu C., Kim M.J., Caron M., Vidal H., et al. Recent advances in the relationship between obesity, inflammation, and insulin resistance. Eur Cytokine Netw 2006, 17(1):4-12.
37. Wellen K.E., Hotamisligil G.S. Inflammation, stress, and diabetes. J Clin Invest 2005, 115(5):1111-1119.
38. Bugianesi E., McCullough A.J., Marchesini G. Insulin resistance: a metabolic pathway to chronic liver disease. Hepatology 2005, 42(5):987-1000.
39. Shoelson S.E., Lee J., Goldfine A.B. Inflammation and insulin resistance. J Clin Invest 2006, 116(7):1793-1801.